Ascendis Pharma (ASND) Tops Q1 EPS by 9c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of EUR0.27, EUR0.09 better than the analyst estimate of EUR0.18. Revenue for the quarter came in at EUR246.6 million versus the consensus estimate of EUR269.95 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Varonis Said To Weigh Sale After Takeover Interest - Bloomberg